226549-07-1

Upstream product

• 4994-14-3 3,3-dimethylcyclohexanone oxime 
• 2979-19-3 3,3-dimethylcyclohexanone 
• 1228449-87-3 benzyl-(3,3-dimethyl-cyclohexyl)-amine 

Downstream Products

• 934765-85-2 phenylmethyl(3,3-dimethylcyclohexyl)carbamate 
• 1154868-64-0 4-(3,3-dimethylcyclohexyl)-3-oxopiperazin-1-ium trifluoroacetate 
• 1357186-00-5 ethyl 1-[(3,3-dimethylcyclohexyl)amino]-5,6,7,8-tetrahydroisoquinoline-4-carboxylate 
• 1309366-14-0 C₃₂H₄₃N₃O 
• 1309363-73-2 (2R)-3-(2-amino-6-o-tolylquinolin-3-yl)-N-(3,3-dimethylcyclohexyl)-2-methylpropanamide 

Relevant academic research and scientific papers

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer?s disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein ring A, B1, B2, B3, L, R1, R4, R5 and m of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer?s Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I

Pyrrolopyrazinyl Urea Kinase Inhibitors

The present invention relates to the use of novel pyrrolopyrazinyl urea derivatives of Formula I, wherein the variables R1, R2, R3, R4, and R5 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.

NOVEL HETEROCYCLE COMPOUNDS

The present invention relates to novel compounds which are antagonist or inverse agonists at an opioid receptor. Such compounds are useful in the treatment of obesity and related diseases and/or conditions in mammals, particularly humans. Methods of making and using such compounds are also disclosed.